compound tirzepatide lawsuit Compounding pharmacies can resume making as FDA reconsiders shortage 🚨BREAKING: Compound Tirzepatide Lawsuit Update!!!

Some forget to eat entirely

We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isnt a failure

PCOS Sisters focuses on long-term strategies that may include: metabolic support medications, insulin-targeted therapies, & hormone-informed maintenance plans GLP-1 treatment at PCOS Sisters is often incorporated into our broader evidence backed metabolic program

At a glance Status : Confirmed GLP-1 receptor agonist use (specific drug not publicly disclosed) Medical context : Pre-existing autoimmune thyroid condition requiring medication Timeline : Public confirmation in 2024 interviews Discontinuation status : Not publicly confirmed whether she has stopped or continues treatment Clinical focus of this page : What peer-reviewed evidence says about GLP-1 discontinuation, regain risk, and maintenance in patients with thyroid comorbidities The Discontinuation Problem: What the Trials Show The single most replicated finding in GLP-1 obesity research is that stopping the medication leads to weight regain